Skip to main content
Proper Name
Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine
Active immunization of individuals 9 months through 55 years of age for the prevention of invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.

Menactra is a sterile, intramuscularly administered vaccine that contains N meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein.

Key Regulatory Milestones

2005 - Menactra was licensed for use and distribution in the US in for individuals 11 through 55 years of age.

2007 - the age range for use was extended to include persons 2 through 10 years of age.

2011 - approved for use in children 9 through 23 months of age.

9/16/2016 - PDUFA Goal Date

04/27/2018 - FDA approval date

Advisory Committee

Did not require input from Vaccines and Related Biological Products Advisory Committee.

Advanced Facts